Clinical trial
Preventive and Personalized Medicine (2021-2023)
Name
1193
Description
This is a GWAS study that aims to identify possible candidate genes associate to arterial hypertension by exploring single nucleotide polymorphism (SNP) in a group of arterial hypertension, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with arterial hypertension
Trial arms
Trial start
2022-03-30
Estimated PCD
2023-01-20
Trial end
2023-01-20
Status
Completed
Treatment
DNA analysis
GWAS
Arms:
Control group, Experimental group:
Size
1200
Primary endpoint
number of SNPs associated with arterial hypertension
1 year
Eligibility criteria
Inclusion Criteria:
* Persons with confirmed arterial hypertension;
* The age of patients is from 18 to 55 years old inclusive;
* Persons of Kazakh nationality, whose paternal and maternal grandparents identify themselves as Kazakhs;
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;
Exclusion Criteria:
* Persons under 18 and over 55;
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Autoimmune diseases;
* Systemic diseases;
* Cancer.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood'}, 'enrollmentInfo': {'count': 1200, 'type': 'ACTUAL'}}
Updated at
2023-03-14
1 organization
1 indication
Organization
Asfendiyarov Kazakh National Medical UniversityIndication
Hypertension